経口生物製剤とバイオシミラーの世界市場レポート 2025年

経口生物製剤とバイオシミラー市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR21.8％で191億3,000万米ドルに成長します。予測期間の成長は、経口生物学的製剤の開発のための旺盛な研究開発活動、注射よりも錠剤への傾倒、不健康なライフスタイルの採用、技術の進歩、経口生物学的製剤の使いやすさ、ヘルスケアへのアクセスの増加、生物学的製剤の償還、バイオシミラーの増加、慢性疾患の有病率の上昇などに起因すると考えられます。予測期間における主な動向としては、潜在的に高い利益率から利益を得るための経口生物製剤市場への投資、生物製剤分野での技術革新率の上昇に伴う生物製剤へのシフト、バイオアベイラビリティを高め皮下経路の副作用を排除するためのマイクロニードル注射器をベースとした薬剤の開発などが挙げられます。

経口生物製剤およびバイオシミラー市場の成長は、関節炎、喘息、がんなどの慢性疾患の有病率の増加によって牽引されると予想されます。長時間労働、身体活動の制限、食生活の乱れなどの不健康な生活習慣が、慢性疾患の罹患率上昇の一因となっています。生物製剤はこれらの疾患の治療において重要な役割を果たし、免疫系を刺激してがんなどの疾患と闘わせる。国連によると、2030年までに世界の死亡原因の70％が慢性疾患になると予想されています。この慢性疾患の急増は、生物製剤およびバイオシミラー市場の拡大を推進する重要な要因です。

経口生物製剤およびバイオシミラー市場の成長は、ヘルスケア支出の増加によっても促進されると予想されます。ヘルスケア支出は金額で測定され、特定期間内にヘルスケア商品とサービスに費やされた総資源を包含します。ヘルスケア支出は、経口生物製剤やバイオシミラーの開発、採用、入手のしやすさに影響を与えます。例えば、メディケア＆メディケイド・サービスセンターは、国民医療費（NHE）の平均成長率がGDPの平均成長率を上回り、その結果、GDPに占める医療費の割合が上昇すると予測しています。医療支出の増加は、慢性疾患の高い有病率と相まって、経口生物製剤およびバイオシミラー市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界経口生物製剤とバイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の経口生物製剤とバイオシミラー市場：成長率分析
• 世界の経口生物製剤とバイオシミラー市場の実績：規模と成長, 2019-2024
• 世界の経口生物製剤とバイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界経口生物製剤とバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の経口生物製剤とバイオシミラー市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• リンパ球調節因子
• インターロイキン阻害剤
• 腫瘍壊死因子α阻害剤
• 免疫刺激剤
• GPCRモジュレーター
• その他のタルピー
• 世界の経口生物製剤とバイオシミラー市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖尿病
• 関節炎とクローン病
• がん
• 感染症
• その他の自己免疫疾患
• その他の病気
• 世界の経口生物製剤とバイオシミラー市場分子タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ワクチン
• タンパク質とペプチド
• モノクローナル抗体
• その他の分子タイプ
• 世界の経口生物製剤とバイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の経口生物製剤とバイオシミラー市場、リンパ球調節薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• T細胞モジュレーター
• B細胞モジュレーター
• スフィンゴシン-1-リン酸受容体モジュレーター
• 世界の経口生物製剤とバイオシミラー市場インターロイキン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IL-1阻害剤
• IL-6阻害剤
• IL-17阻害剤
• IL-23阻害剤
• 世界の経口生物製剤とバイオシミラー市場腫瘍壊死因子アルファ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• TNF-α阻害薬
• TNF-αを標的とするモノクローナル抗体
• 世界の経口生物製剤とバイオシミラー市場、免疫刺激剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サイトカイン
• 免疫チェックポイント阻害剤
• アジュバント
• 世界の経口生物製剤とバイオシミラー市場GPCRモジュレーターのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• アゴニスト
• 敵対者
• バイアスリガンド
• 世界の経口生物製剤とバイオシミラー市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞ベースの治療法
• 遺伝子治療
• 併用療法

第7章 地域別・国別分析

• 世界の経口生物製剤とバイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の経口生物製剤とバイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 経口生物製剤とバイオシミラー市場：競合情勢
• 経口生物製剤とバイオシミラー市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
  • ALK-Abello Overview, Products and Services, Strategy and Financial Analysis
  • Aimmune Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• VIVUS Inc
• Materia Medica Holding
• VECTOR-MEDICA
• Henlius
• Innovent Biologics
• Bio-Thera
• Hisun Pharma
• 3SBio
• Beijing ShuangLu Pharmaceuticals
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceuticals
• Biocon
• Dr.Reddy's
• Mylan
• Kyowa Hakko Kirin

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 経口生物製剤とバイオシミラー市場2029：新たな機会を提供する国
• 経口生物製剤とバイオシミラー市場2029：新たな機会を提供するセグメント
• 経口生物製剤とバイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biologics represent pharmaceuticals derived from living cells through highly intricate technology, whereas biosimilars are designed to function similarly to biologics but are not exact replicas. Within the oral biologics and biosimilar market, these drugs are administered orally to specifically target conditions such as Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious ailments, as well as to address chronic diseases such as diabetes, arthritis, and cancer.

The primary therapy categories for oral biologics and biosimilars encompass lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, immunostimulants, GPCR modulators, and others. Interleukin inhibitors serve as immunosuppressive medications that impede the function of interleukins. Various diseases treated include asthma, Crohn's disease, cancer, infectious disease, other autoimmune conditions, and more, employing molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and other therapies. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilars market statistics, including oral biologics and biosimilars industry global market size, regional shares, competitors with an oral biologics and biosimilars market share, detailed oral biologics and biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilars industry. This oral biologics and biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $7.04 billion in 2024 to $8.69 billion in 2025 at a compound annual growth rate (CAGR) of 23.5%. The growth in the historic period can be attributed to increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due to cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $19.13 billion in 2029 at a compound annual growth rate (CAGR) of 21.8%. The growth in the forecast period can be attributed to robust research and development activities for the development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases. Major trends in the forecast period include investing in the oral biologics market to benefit from potentially strong profit margins, shifting to biologics, as the innovation rate is increasing in that field, developing microneedle injectors-based drugs to increase the bioavailability and eliminating side effects of subcutaneous route.

The growth of the oral biologics and biosimilar market is expected to be driven by the increasing prevalence of chronic diseases such as arthritis, asthma, and cancer. Unhealthy lifestyle factors, including long working hours, limited physical activity, and poor dietary habits, contribute to the rising incidence of chronic diseases. Biologics play a crucial role in treating these conditions, stimulating the immune system to combat diseases such as cancer. According to the United Nations, it is anticipated that chronic diseases will account for 70% of global fatalities by 2030. This surge in chronic diseases is a significant factor propelling the expansion of the biologics and biosimilar market.

The growth of the oral biologics and biosimilars market is also expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, measured in monetary terms, encompasses the total resources spent on healthcare goods and services within a specific period. The implications of healthcare expenditure impact the development, adoption, and accessibility of oral biologics and biosimilars. For instance, the Centers for Medicare & Medicaid Services project that the average National Health Expenditures (NHE) growth will exceed the average GDP growth, resulting in a rise in health spending as a share of GDP. The increasing healthcare expenditure, coupled with the high prevalence of chronic diseases, is expected to drive the growth of the oral biologics and biosimilars market.

The development of new insulin biosimilars is a prominent trend gaining traction in the oral biologics and biosimilar market. Major players in this market are investing in creating biosimilar versions of insulin to capture a larger market share. For example, in January 2023, Amgen, a US-based biotechnology firm, launched Amjevita, a biosimilar to Humira, reflecting advancements in the creation of insulin biosimilars. The goal is to reduce costs and enhance access to essential treatments. Amjevita offers a more affordable option for conditions such as arthritis and Crohn's disease, while insulin biosimilars aim to make diabetes treatments more accessible. These developments are fostering competition and driving innovation in the biologics sector. Amgen is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics.

The role of technology is anticipated to continue driving market growth, particularly in the area of physiology simulation modeling. Advancements in this field contribute to greater efficiencies, such as Eli Lilly and Pfizer utilizing Amazon's Elastic Compute Cloud (EC2) platform for simulation models in early drug discovery. This approach significantly reduces the time required for simulations compared to traditional methods. The adoption of technology, especially in physiological simulation modeling, is expected to play a pivotal role in the further development of the oral biologics and biosimilar market.

In September 2023, Biocon Limited, an Indian pharmaceutical company, completed the acquisition of Eywa Pharma Inc. for $7.7 million. This strategic acquisition enhances Biocon's manufacturing infrastructure, ensuring a continuous supply and providing capacities for oral solid dosage products ahead of schedule. Eywa Pharma, Inc., a US-based pharmaceutical company specializing in oral biologics and biosimilars, aligns with Biocon's commitment to diversify and strengthen its market position.

Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abello, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consists of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
• 2) By Disease: Diabetes, Arthritis and Crohn's Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
• 3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
• 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• Subsegments:
• 1) By Lymphocyte Modulators: T-Cell Modulators; B-Cell Modulators; Sphingosine-1-Phosphate Receptor Modulators
• 2) By Interleukin Inhibitors: IL-1 Inhibitors; IL-6 Inhibitors; IL-17 Inhibitors; IL-23 Inhibitors
• 3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-a Blockers; Monoclonal Antibodies Targeting TNF-a
• 4) By Immunostimulants: Cytokines; Immune Checkpoint Inhibitors; Adjuvants
• 5) By GPCR Modulators: Agonists; Antagonists; Biased Ligands
• 6) By Other Therapies: Cell-Based Therapies; Gene Therapies; Combination Therapies
• Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline; Novo Nordisk; ALK-Abello; Aimmune Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Trends And Strategies

4. Oral Biologics & Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Oral Biologics & Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oral Biologics & Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oral Biologics & Biosimilars Market Growth Rate Analysis
• 5.4. Global Oral Biologics & Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oral Biologics & Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oral Biologics & Biosimilars Total Addressable Market (TAM)

6. Oral Biologics & Biosimilars Market Segmentation

• 6.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lymphocyte Modulators
• Interleukin Inhibitors
• Tumor Necrosis Factor-Alpha Inhibitors
• Immunostimulants
• GPCR Modulators
• Other Tharpies
• 6.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetes
• Arthritis and Crohn's Disease
• Cancer
• Infectious Disease
• Other Autoimmune Disease
• Other Diseases
• 6.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vaccines
• Proteins and Peptides
• Monoclonal Antibodies
• Other Molecule Types
• 6.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Lymphocyte Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• T-Cell Modulators
• B-Cell Modulators
• Sphingosine-1-Phosphate Receptor Modulators
• 6.6. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IL-1 Inhibitors
• IL-6 Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors
• 6.7. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Tumor Necrosis Factor-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• TNF-a Blockers
• Monoclonal Antibodies Targeting TNF-a
• 6.8. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Immunostimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokines
• Immune Checkpoint Inhibitors
• Adjuvants
• 6.9. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of GPCR Modulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Agonists
• Antagonists
• Biased Ligands
• 6.10. Global Oral Biologics & Biosimilars Market, Sub-Segmentation Of Other Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cell-Based Therapies
• Gene Therapies
• Combination Therapies

7. Oral Biologics & Biosimilars Market Regional And Country Analysis

• 7.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilars Market

• 8.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Biologics & Biosimilars Market

• 9.1. China Oral Biologics & Biosimilars Market Overview
• 9.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Biologics & Biosimilars Market

• 10.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Biologics & Biosimilars Market

• 11.1. Japan Oral Biologics & Biosimilars Market Overview
• 11.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Biologics & Biosimilars Market

• 12.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Biologics & Biosimilars Market

• 13.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Biologics & Biosimilars Market

• 14.1. South Korea Oral Biologics & Biosimilars Market Overview
• 14.2. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Biologics & Biosimilars Market

• 15.1. Western Europe Oral Biologics & Biosimilars Market Overview
• 15.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Biologics & Biosimilars Market

• 16.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Biologics & Biosimilars Market

• 17.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Biologics & Biosimilars Market

• 18.1. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Biologics & Biosimilars Market

• 19.1. Italy Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Biologics & Biosimilars Market

• 20.1. Spain Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilars Market

• 21.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
• 21.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Biologics & Biosimilars Market

• 22.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Biologics & Biosimilars Market

• 23.1. North America Oral Biologics & Biosimilars Market Overview
• 23.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Biologics & Biosimilars Market

• 24.1. USA Oral Biologics & Biosimilars Market Overview
• 24.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Biologics & Biosimilars Market

• 25.1. Canada Oral Biologics & Biosimilars Market Overview
• 25.2. Canada Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Biologics & Biosimilars Market

• 26.1. South America Oral Biologics & Biosimilars Market Overview
• 26.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Biologics & Biosimilars Market

• 27.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Biologics & Biosimilars Market

• 28.1. Middle East Oral Biologics & Biosimilars Market Overview
• 28.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Biologics & Biosimilars Market

• 29.1. Africa Oral Biologics & Biosimilars Market Overview
• 29.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Oral Biologics & Biosimilars Market Competitive Landscape
• 30.2. Oral Biologics & Biosimilars Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. ALK-Abello Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Aimmune Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Oral Biologics & Biosimilars Market Other Major And Innovative Companies

• 31.1. VIVUS Inc
• 31.2. Materia Medica Holding
• 31.3. VECTOR-MEDICA
• 31.4. Henlius
• 31.5. Innovent Biologics
• 31.6. Bio-Thera
• 31.7. Hisun Pharma
• 31.8. 3SBio
• 31.9. Beijing ShuangLu Pharmaceuticals
• 31.10. Qilu Pharmaceutical
• 31.11. Shanghai Fosun Pharmaceuticals
• 31.12. Biocon
• 31.13. Dr.Reddy's
• 31.14. Mylan
• 31.15. Kyowa Hakko Kirin

32. Global Oral Biologics & Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

34. Recent Developments In The Oral Biologics & Biosimilars Market

35. Oral Biologics & Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Oral Biologics & Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oral Biologics & Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oral Biologics & Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer